Dr. Janet McNicholas is noted for her patent-related achievements in the areas of biotechnology, pharmaceutical products, and medical products. Her experience includes more than 25 years of practice as a patent attorney, and she serves as patent counsel to biotechnology and pharmaceutical companies, including start-up and emerging growth companies financed by private equity and venture capital investors.
Janet advises clients in the development, management, and enforcement of worldwide patent portfolios. She writes and prosecutes patent applications for a broad range of life science technologies, advises clients in licensing and agreement matters, and is experienced in biopharma litigation and opposition matters. Her practice regularly includes conducting patentability, freedom-to-operate, infringement, and validity assessments; evaluating intellectual property portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals; and mining developing and mature patent portfolios for opportunities to maximize value.
Prior to practicing law, Janet conducted research in immunology, molecular biology, biochemistry, and genetics at the University of Illinois as a pre-doctoral student and then at Stanford University and at the California Institute of Technology as a post-doctoral fellow of the Arthritis Foundation.
Janet has spoken at national and international scientific, business, and legal conferences on patent matters relating to recombinant biologicals, therapeutic antibodies, bioprocessing/bioproduction, biofuels, biosimilars/follow-on biologics, pharmaceuticals, Hatch-Waxman Act, branded and generic drug development, medical devices, and partnering/outsourcing.
Janet is a member of the American Bar Association, American Intellectual Property Law Association, San Francisco Intellectual Property Law Association, Intellectual Property Law Association of Chicago, Chinese American Biopharmaceutical Society, Silicon Valley Indian Professionals Association, and TiE Silicon Valley.
NGM develops global patent portfolio for beta-klotho antibodies
NGM establishes global patent portfolio related to novel protein therapies